Introduction
Duchenne muscular dystrophy (DMD) is a degenerative muscle disease characterized by a lack of dystrophin expression in the sarcolemma, a condition that leads to progressive muscle weakness. 1 In the heart, the reduced levels or absence of dystrophin in patients causes cardiac muscle degeneration and the gradual development of dilated cardiomyopathy. 2 Dystrophin-deficient myocardium is the result of either a mutation in the X-linked dystrophin gene (as in DMD) 2 or a virus-mediated cleavage of the dystrophin protein. 3, 4 The functional loss of the dystrophin protein compromises the structural integrity of the sarcolemma, resulting in progressive and irreversible degeneration of cardiomyocytes. 5, 6 To date, researchers using cell or gene therapy have made only a few attempts to correct dystrophin deficiency in the hearts of dystrophic animals. [7] [8] [9] [10] Cellular cardiomyoplasty, a procedure involving the transplantation of exogenous cells into the heart, is a possible approach by which to regenerate diseased myocardium, deliver therapeutic genes, and improve cardiac function. 11 Researchers have investigated the use of various cell types for cardiac repair, including cardiomyocytes, fibroblasts, embryonic stem cells, endothelial progenitor cells, bone marrow-derived cells, hematopoietic stem cells, mesenchymal stem cells, smooth muscle cells, skeletal muscle-derived cells, 12 and the recently identified cardiac stem cells. [13] [14] [15] [16] [17] Notably, numerous research groups have found that skeletal muscle-derived cells can successfully engraft in the heart and improve cardiac performance in animal models. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Currently, autologous skeletal myoblasts are being used in clinical trials for cardiac repair. [31] [32] [33] [34] [35] Our research group has isolated populations of murine skeletal muscle-derived stem cells (MDSCs) by using a modified preplate technique. 36, 37 MDSCs exhibit stem cell-like properties and appear to be distinct from later-stage myogenic cell populations such as satellite cells and myoblasts. 37 In addition, MDSCs can undergo differentiation toward muscle, bone, neural, endothelial, and hematopoietic lineages. [36] [37] [38] By transplanting MDSCs into the dystrophic skeletal muscle of mdx mice, we have previously shown that MDSCs generate large grafts containing numerous dystrophin-positive myofibers. 37 Here, we transplanted MDSCs into the dystrophin-deficient hearts of adult mdx mice. We sought to determine if the MDSCs could (a) engraft and persist in the heart, (b) regenerate donor-derived myocytes that express both reporter (LacZ) and therapeutic (dystrophin) genes, and (c) acquire a cardiac-specific phenotype after transplantation.
Results

Characterization of the nLacZ-Expressing MDSCs in vitro
We transduced MDSCs with a retrovirus containing a nuclear LacZ (nLacZ) reporter gene. We then stained these cells in vitro with X-gal substrate to confirm expression of the nLacZ reporter gene (Figure 1a) . Approximately 50% of the MDSCs expressed nLacZ in vitro immediately before delivery by intracardiac injection.
Since we isolated the MDSCs from normal skeletal muscle for injection into dystrophin-deficient myocardium, we tested the cells' ability to express dystrophin after differentiation into myotubes. In low serumcontaining medium, MDSCs were able to differentiate into dystrophin-expressing myotubes (Figure 1b) .
Validation of cardiac and skeletal muscle-specific markers
The cardiac a-myosin heavy chain (a-MHC) and cardiac Troponin I (cTnI) antibodies reacted specifically to cardiac muscle ( Figure 1c , top row, red) and not skeletal muscle ( Figure 1c , bottom row). These results, which confirm the cardiac specificity of the a-MHC and cTnI antibodies in murine tissue, validate the use of these markers to indicate any cardiac-phenotypic changes of the transplanted MDSCs, particularly because the injected MDSCs were of skeletal muscle origin. In addition, an antibody (MY32) against fast skeletal myosin heavy chain (fast sk. MHC) reacted specifically to skeletal muscle ( Figure 1c , bottom row, green) and not cardiac muscle ( Figure 1c , top row).
MDSCs generate large grafts in the mdx heart
We injected MDSCs into the left ventricular myocardium of dystrophic mdx mice. After injecting the MDSCs, we tracked their fate by observing expression of the nLacZ reporter gene and dystrophin protein. At 2 weeks after implanting the cells, we observed that the injected cells had formed a graft within the myocardium containing numerous myocytes expressing nLacZ (blue) (Figure 2a , top row). We validated the persistence of the graft 4 and 8 weeks after implantation (Figure 2a , top row). On serial sections of the same hearts, dystrophin expression (green) was visible ( Figure 2a , bottom row) and colocalized with the nLacZ expression observed 2, 4, and 8 weeks after injection (Figure 2a , top row); this finding indicates that the MDSCs regenerated numerous dystrophin-expressing myocytes within the dystrophic myocardium. We observed fewer nLacZ[+] nuclei than dystrophin-positive myocytes (Figure 2a ): Approximately 50% of the MDSCs expressed nLacZ in vitro immediately before injection, whereas every MDSC contained the normal dystrophin gene. The nLacZ [-] region (ie, the host myocardium) surrounding the graft was negative for dystrophin, as one would expect to be the case in a dystrophic host (Figure 2a) . The dystrophinpositive grafts consisted primarily of terminally differentiated skeletal myofibers as indicated by their expression of fast sk. MHC (red, Figure 2b ). In addition, these fast sk. MHC-positive donor-derived cells formed multinucleated myofibers (Figure 2c ).
Colocalization of dystrophin and cardiac markerexpressing myocytes at the border of the graft and the host myocardium Initially, we sought to determine whether these nLacZand dystrophin-expressing grafts expressed cardiacspecific markers. After double staining for both dystrophin and cardiac a-MHC at various time points after transplantation, we found that the majority of the dystrophin-expressing (green) myocytes located within the center of the graft did not express cardiac a-MHC (red) (Figure 3a , 'graft' column). However, we did observe colocalization of dystrophin and cardiac a-MHC in a few cells located at the border of the graft and the host myocardium (Figure 3a ; see arrows in 'graft-host border' columns).
Since the presence of colocalized myocytes expressing dystrophin and cardiac a-MHC could be attributable to the presence of revertant dystrophin-positive host Figure 1 Validation of donor-specific markers and of cardiac and skeletal muscle-specific antibodies. (a) A population of MDSCs was genetically engineered to express the nLacZ reporter gene. Positive staining (blue) is localized to the nucleus of the cells in vitro. (b) When cultured in low serum-containing medium in vitro, the MDSCs differentiated into multinucleated myotubes expressing dystrophin (red). (c) Cardiac-specific antibodies against a-myosin heavy chain (a-MHC) and cardiac Troponin I (cTnI) are reactive with cardiac muscle (red, top row 'cardiac'); however, they do not cross-react with skeletal muscle (bottom row 'skeletal'). Antibodies against fast skeletal myosin heavy chain (fast sk. MHC) react exclusively with skeletal muscle (green, bottom row 'skeletal') and not cardiac muscle (top row 'cardiac'). Nuclei were revealed with DAPI stain (blue). Scale bars equal 100 mm (a, b) and 20 mm (c).
Skeletal muscle stem cells for the mdx heart TR Payne et al cardiomyocytes in the mdx mouse, 39 we used nLacZ expression to validate the donor origin of these myocytes. Specifically, we repeated the dystrophin/cardiac a-MHC double staining on cryosections prestained in X-gal substrate to enable colocalization of the immunostains with donor-specific nLacZ expression. We observed donor cells containing an nLacZ[+] nucleus and coexpressing both dystrophin and cardiac a-MHC at the border of the graft and host myocardium (Figure 3b ). To quantitatively evaluate the nLacZ and cardiac a-MHC colocalization, we counted both the nLacZ[+] nuclei that colocalized with cardiac a-MHC and the total number of nLacZ[+] nuclei in the five sections containing the largest grafts in each MDSC-injected heart. It is important to note here that we used nLacZ instead of dystrophin as the primary marker to identify and quantify the donor cells that did and did not colocalize with cardiac a-MHC (Figure 3b and c) to exclude any revertant dystrophinpositive host cardiomyocytes. Using these data, we determined the percentage of nLacZ and cardiac a-MHC colocalization within each heart (n ¼ 10) 2, 4, 8, and 12 weeks after implantation ( Figure 3c ). The percent averages indicate that 3.0% of the donor cells expressed cardiac a-MHC at 2 weeks after transplantation (n ¼ 3), 4.0% at 4 weeks (n ¼ 3), 5.1% at 8 weeks (n ¼ 3), and 0.6% at 12 weeks (n ¼ 1) (Figure 3c ).
Expression of a hybrid cardiac and skeletal muscle phenotype by the donor myocytes
To further investigate the cardiac and/or skeletal muscle phenotype of the donor-derived nLacZ[+] cells after implantation, we performed additional multilabel stainings to detect cells coexpressing the cardiac-specific marker cTnI and the skeletal muscle-specific marker fast sk. MHC within sections of the MDSC-injected hearts. Similar to our finding in Figure 2b and c, our observations at all time points revealed that most of the nLacZ donor cells were expressing fast sk. MHC and were negative for cTnI, which indicates again that the majority of the graft was composed of skeletal muscle myofibers. However, each heart contained a few nLacZ[+] cells that expressed cTnI and, like the a-MHC[+] cells observed in 
Evaluation of fusion between MDSCs and host cardiomyocytes
To determine if the acquisition of the cardiac phenotype by the implanted MDSCs was the result of fusion with Figure 3 Some transplanted MDSCs exhibit a cardiac phenotype. (a) Double staining for both cardiac-specific a-MHC (red) and dystrophin (green) revealed very little colocalization throughout most regions of the grafts (as shown in first column labeled 'graft'). However, we observed some colocalization (see arrows) of dystrophin (green) and a-MHC (red) at the border of the graft and the host myocardium (as shown in second and third columns labeled 'graft-host border'). Scale bar for images in first column ('graft'), 100 mm; scale bar for second column, 50 mm; scale bar for third column, 20 mm. However, a small number of donor cells in each injected heart exhibited evidence of fusion with host cardiomyocytes.
Evaluation of connexin43 gap junction protein expression
We stained the cell-injected hearts with antibodies specific for the connexin43 gap junction protein, which is a molecular attribute of electrical coupling between cardiomyocytes. The host myocardium displayed a typical expression pattern of connexin43 (green) between cardiomyocytes, identified by cTnI staining (red) ( Figure  6a ). In contrast, the donor-derived fast sk. MHC[+] myocytes (purple) within the graft did not express connexin43 (Figure 6b ). In addition, fast sk. MHC[+] myofibers (purple) did not form connexin43 gap junctions (green) with host cardiomyocytes (red) ('graft-host myocardium border', Figure 6c ). Skeletal muscle stem cells for the mdx heart TR Payne et al
Assessment of scar tissue at the border of the graft and the host myocardium
Numerous donor-labeled cells that acquired a cardiac phenotype through fusion with host cardiomyocytes were visible at the border of the graft and the host myocardium. However, the presence of scar tissue at this interface may have hindered the fusion and coupling of additional donor cells with host cardiomyocytes. To assess scar tissue formation (as indicated by the accumulation of collagen) in the graft region, we used the Masson Trichrome stain to label collagen (blue), myofibers (red), and nuclei (black). The graft (GR) in the Trichrome-stained sections (Figure 7b , e) was identified by colocalization with serial sections stained for nLacZ expression (Figure 7a, d) . We observed minimal collagen (blue) expression in the host myocardium (HM), but observed collagen expression throughout the grafts (GR) at both 4 ( Figure 7b , top row) and 8 weeks after implantation (Figure 7e ; bottom row, see arrows). Moreover, higher magnification revealed collagen overgrowth at the border of the graft and the host myocardium, indicating a potential barrier to the fusion of MDSCs with host cardiomyocytes (Figure 7c , f; see yellow arrows).
Donor cells contribute to blood vessel structures in the heart
To determine whether some donor cells participated in the formation of blood vessel structures in the heart, we double stained for both nLacZ and CD31 (also known as PECAM), a marker expressed by endothelial cells (Figure  8a-c) . We used nLacZ rather than dystrophin to identify donor cells, because nonmyocytes such as endothelial cells typically do not express dystrophin. In the cellinjected hearts, the majority of CD31[+] capillary structures (brown) within the graft did not colocalize with nLacZ (blue) and thus appeared to be host derived (Figure 8a, b) . However, we did observe a few donor cells that displayed colocalization of both nLacZ (blue) and CD31 (brown) (Figure 8c ).
Discussion
The data from this study demonstrate that MDSCs can generate numerous dystrophin-positive myocytes after intracardiac transplantation within the dystrophic hearts of mdx mice. These dystrophin-positive grafts persisted for at least 12 weeks. It is apparent from these grafts that Skeletal muscle stem cells for the mdx heart TR Payne et al
MDSCs primarily fuse with each other and generate numerous dystrophin-positive skeletal myofibers even when injected into the heart. Our results also suggest that donor-derived cells contributed to the formation of blood vessel-like structures in the heart. Since the mdx heart displays only very mild cardiomyopathy, this study did not allow us to determine if the regeneration of dytrophin-expressing myocytes as a product of the MDSC transplantation could significantly improve global cardiac function. In addition to exhibiting the ability to fuse and create numerous multinucleated skeletal myofibers in the mdx heart, the injected MDSCs demonstrated cellular fusion with host cardiomyocytes located at the border of the graft and the host myocardium. Our observations of (a) donor cells expressing a hybrid cardiac and skeletal muscle phenotype ( Figure 4 ) and (b) numerous donor cells expressing a cardiac phenotype and containing host Y-chromosome-bearing nuclei ( Figure 5 ) provide evidence of fusion between MDSCs and host cardiomyocytes located in this region. Various in vitro and in vivo studies have shown that different donor cell populations (eg, hematopoietic stem cells, bone marrow cells, neuronal cells, and cardiac stem cells) can spontaneously fuse with the cells of recipients and adopt the recipient cells' phenotype. 17, [40] [41] [42] [43] [44] [45] Our results regarding the fusion of MDSCs and host cardiomyocytes are in agreement with two recent studies using myogenic cells. 46, 47 These studies have reported that C2C12 myoblasts 47 and primary myoblast cultures 46 implanted into mouse hearts also display the ability to fuse with host cardiomyocytes at the border of the graft and the host myocardium.
It is interesting to note that of the 50 nLacZ nucleus that did not stain positive for nLacZ, we still considered these hybrid cells to be the product of fusion between donor cells and host cardiomyocytes. In these 40 'fused' cells, the lack of nLacZ in the Ychromosome-bearing nuclei is explainable on the basis of the nuclear domain theory, which proposes that products from an individual nucleus within a multinucleated fused cell will only migrate a limited distance. 48 Thus, the donor nucleus and host nucleus in these fused cells might not have been located in sufficient proximity for the donor nLacZ gene product to migrate into the host nucleus.
The primary goal of the sex-mismatched donor and host transplantation experiment was to detect fusion of donor MDSCs with host cardiomyocytes. While analyzing our results, however, we observed numerous nLacZ donor-derived myocytes that expressed cTnI but did not contain the Y-chromosome-bearing nucleus indicative of a fusion event (Figure 5b ). Although these donor-derived myocytes could have arisen via differentiation of MDSCs into cardiomyocytes, the inability to detect Y-chromosome-bearing nuclei in these cells might also be attributed to technical limitations associated with the detection of the Y-chromosome in situ. Further experimentation is necessary to determine if MDSCs are capable of undergoing true cardiac differentiation.
We did not observe connexin43 gap junction connections between donor myocytes or between donor and host myocytes at the graft-myocardial border. The lack of gap junction complexes may signify both electrical isolation of the graft from the myocardium and the potential for cardiac arrhythmias, 46, 49 and therefore could be a major limitation associated with the use of MDSCs and other muscle-derived cell types for cardiac repair. We did not monitor for arrhythmias in this study; however, a previous study using surface electrocardiogram did not detect arrhythmias in murine hearts engrafted with C2C12 myoblasts. 22 Future studies will investigate the potential of engrafted MDSCs to induce arrhythmias.
Gap junction connections and fusion of transplanted MDSCs with host cardiomyocytes require intimate interaction of the donor cells with the host cardiomyocytes. Our results revealed scar tissue present at the graft and host myocardium interface and within the graft itself. We posit that the scar tissue forms a barrier between the graft and the host myocardium and, in so doing, may prevent donor cells from potentially fusing or coupling via gap junctions with host cardiomyocytes. The use of antifibrosis agents in combination with intracardiac cell transplantation may help to block scar tissue formation in the graft and enhance the integration of the graft with the host myocardium.
In summary, this study establishes that MDSCs implanted into dystrophic mdx hearts can generate large grafts containing numerous dystrophin-expressing myocytes. Although the graft consisted primarily of skeletal muscle myofibers, a small number of donor-derived myocytes located at the border of the graft and the host myocardium expressed a hybrid cardiac-skeletal phenotype and fused with host cardiomyocytes. Most donorderived myocytes did not form connexin43 gap junctions with each other or with host cardiomyocytes. Scar tissue that developed at the graft-host myocardium interface may impede the fusion and coupling of MDSCs with host cardiomyocytes. A few donor-derived cells within the graft also expressed an endothelial-specific marker. In conclusion, this study provides insight into the biology and behavior of MDSCs after intramyocardial transplantation in the mdx heart and their potential application for the treatment of DMD-induced cardiomyopathy.
Methods Animals
The Institutional Animal Care and Use Committee, Children's Hospital of Pittsburgh, has approved the use Skeletal muscle stem cells for the mdx heart TR Payne et al of animals and surgical procedures performed in this study (protocol 6/02).
The MDSCs were isolated from the skeletal muscle of female normal neonatal (3-5-day-old) mice (C57BL/6J; Jackson Laboratory) as previously described. 37 These cells were injected into the hearts of 10-12-week-old male mdx/SCID mice (n ¼ 10, C57BL/10ScSn-Dmd mdx crossed with C57BL/6J-Prkdc scid /SzJ). These mice are mutant for both the dystrophin and Prkdc genes, and therefore possess an mdx and SCID phenotype (mdx/SCID). We used this dystrophic mouse model with a SCID background because the donor MDSCs were derived from allogeneic muscle and were genetically engineered to express the bacterial b-galactosidase protein, a potential immunogen.
Isolation and culture of MDSCs
MDSCs were isolated via the previously described modified preplate technique. 36, 37, 50 MDSCs were cultured in proliferation medium (PM), which contained DMEM, 10% fetal bovine serum, 10% horse serum (HS), 1% penicillin/streptomycin, and 0.5% chick embryo extract. 37 Low serum-containing medium containing DMEM, 5% HS, and 1% penicillin/streptomycin was used to induce MDSCs to form myotubes in vitro. Dystrophin expression by the myotubes in vitro was determined by immunocytochemistry, as described previously. 51 
MDSCs transduced with a retrovirus containing the nLacZ reporter gene
To enable tracking of the cells after injection into the heart, the MDSCs were genetically engineered to express the nLacZ reporter gene. MDSCs were infected with the retroviral vector MFG-NB containing a modified LacZ gene (nls-LacZ) (gift from P Robbins), which includes a nuclear-localization sequence cloned from the simian virus 40 (SV40) large tumor antigen and is transcribed from the long terminal repeat. 52 Retroviral infection of MDSCs was performed three times, and the transduced cells were assayed for nLacZ expression, as described previously. 37 
Intracardiac cell transplantation
Mice were anesthetized with a gaseous mixture of isoflurane and oxygen and were mechanically ventilated. The heart was exposed via a left thoracotomy, and a 30 G needle was used to inject 10 ml of PBS solution containing 300 000 MDSCs into the left ventricular free wall. Aseptic technique was maintained throughout the procedure. At various time points after transplantation, mice were killed and their hearts were harvested and frozen in 2-methylbutane precooled in liquid nitrogen. The frozen tissue was then serially cryosectioned into 8 mm-thick sections.
Histology and Trichrome staining
Previously described techniques were used to stain sections for both nLacZ and eosin. 37 The Masson Modified IMEB Trichrome Stain Kit (IMEB), which stains collagen (blue), muscle fibers (red), and nuclei (black), was used according to the manufacturer's instructions to stain additional sections.
Staining for both cardiac and skeletal muscle-specific markers
Cryosections were fixed in 2% formaldehyde (Sigma) and then multilabel stained for cardiac a-MHC/dystrophin, nLacZ/cardiac a-MHC/dystrophin, nLacZ/cTnI/ fast sk. MHC, nLacZ/dystrophin/fast sk. MHC/cTnI, nLacZ/cTnI/Cx43/fast sk. MHC, or nLacZ/CD31. Each step of these double and triple stains was performed as follows. Sections were stained for nLacZ expression in X-Gal solution overnight at 371C. The MOM Kit (Vector) was used according to the manufacturer's instructions to apply mouse anticardiac a-MHC antibody (1:2 hybridoma supernatant; ATCC) to the sections. Rabbit antidystrophin antibody (1:1000; gift from T. Partridge) was incubated overnight at 41C and subsequently reacted with FITC-conjugated anti-rabbit IgG (1:100; Sigma) for 90 min at room temperature (RT). Goat anti-cTnI antibody (1:25 000; Scripps) was incubated for 2 h at RT and then reacted with Cy3-conjugated anti-goat IgG antibody (1:100; Sigma) for 60 min. The MOM Kit was used according to the manufacturer's instructions to stain mouse anti-fast sk. MHC antibodies (1:400; Sigma). Rabbit anti-connexin43 antibody (1:250; Chemicon) was applied for 2 h and then reacted with donkey anti-rabbit IgG-AlexaFluor 488 conjugated (1:200; Molecular Probes) for 60 min. Rat anti-CD31 (1:100; BD Pharmingen) was stained using Vectastain ABC Kit for Rat IgG (Vector). Nuclei were revealed with 4 0 ,6-diamidino-2-phenylindole (DAPI) stain (100 ng/ml; Sigma), and all sections were mounted with Vectashield medium (Vector).
Detection of fusion
Cryosections from male hearts injected with female MDSCs were fixed with cold 4% formalin (Sigma), rinsed with PBS, and incubated in X-Gal solution overnight at 371C. After being rinsed in PBS, sections were blocked in 10% rabbit serum (Vector) for 60 min at RT, and then were incubated with goat anti-cardiac Troponin I antibody (Scripps) for 2 h at RT. After several rinses in PBS, biotinylated anti-goat IgG antibody (Vector) was applied to the sections for 60 min at RT. Streptavidin, Oregon Greent 488 conjugate (Molecular Probes) was subsequently applied for 10 min. Following the immunostaining for cTnI, we used FISH on these same sections to detect the murine Y-chromosome. A mouse Y-chromosome-specific probe labeled with digoxigenin (gift from R Stanyon) and a hybridization mixture were denatured at 751C for 10 min and allowed to reanneal for 60-90 min at 371C. This mixture was applied for 18-24 h at 371C. The hybridized Y-chromosomespecific probe was detected fluorescently by incubating the sections with sheep anti-digoxigenin FAB fragments coupled with Rhodamine (Roche) for 45 min at 371C. Nuclei were revealed with DAPI stain (100 ng/ml; Sigma), and all sections were mounted with Vectashield medium (Vector).
Microscopy
All fluorescent and bright-field microscopy was performed with either (a) a Nikon Eclipse E800 microscope equipped with a Spot digital camera and software system (v. 3.0.4; Diagnostic Instruments) or (b) a Leica DMIRB microscope equipped with a Retiga 1300 digital Skeletal muscle stem cells for the mdx heart TR Payne et al camera (Q Imaging) and Northern Eclipse software system (v. 6.0; Empix Imaging, Inc.).
